Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lung Adenocarcinoma Treatment Market

Lung Adenocarcinoma Treatment Market Share

Report ID: GMI11125
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Lung Adenocarcinoma Treatment Market Share

The market is highly competitive, featuring a mix of major global players and smaller to medium-sized companies vying for market share. A key aspect of market strategy involves the continuous introduction of innovations, such as EGFR inhibitors, ALK inhibitors, and combination therapies. Notably, prominent industry players exert considerable influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers play crucial roles in strengthening market positions and expanding global footprints amidst evolving regulatory landscapes.

Lung Adenocarcinoma Treatment Market Companies

Some of the eminent market participants operating in the lung adenocarcinoma treatment industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The lung adenocarcinoma treatment market size was valued at around USD 5.1 billion in 2023 and is estimated to grow at 10.5% CAGR from 2024 to 2032, driven by the rising incidence of lung cancer.

The stage IV lung adenocarcinoma treatment segment was valued at USD 3.1 billion in 2023, driven by the growing adoption of advanced treatment options like targeted therapies and immunotherapies.

North America lung adenocarcinoma treatment market is forecasted to reach USD 5.7 billion by 2032, driven by the introduction of novel therapies.

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd among others.